drugset / Trial / NCT01058850

Phase I Rindopepimut After Conventional Radiation in Children w/ Diffuse Intrinsic Pontine Gliomas

NCT01058850

NaSingle-groupOpen-labelTreatment

Summary

This is a research study of patients with diffuse intrinsic pontine gliomas. We hope to learn about the safety and efficacy of treating pediatric diffuse intrinsic pontine glioma patients with the EGFRvIII peptide vaccine after conventional radiation.

Timeline

Start
2011-06
Primary completion
2013-09
Completion
2013-09

Drugs

EvaluationDrugModalityDoseRoute
Subject rindopepimut Vaccine 250 ug Other
Subject rindopepimut Vaccine 500 ug Other